Only on approval. I can see $10 this year as trials will be starting. Data is likely sometime next year. The true inflection point will be the AD phase 2/3 readout.
Curious,where is the street putting our value of 250 mln from? Rett`s potential,Parkensons,or Alzheimers? Because at 250 mln market cap for any one of these Applications is ridiculous,so realistically what do you think the potential market cap is for each,if all 3 are a success?